A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease
(SCD) in both adults and children. ICA-17043 is a potent and specific inhibitor of a channel
in human red blood cells (RBCs) that blocks RBC dehydration. ICA-17043 is expected to inhibit
RBC dehydration and thus should prevent or delay the sickling process. By reducing sickled
cells, an improvement in anemia, a reduction in painful crises, and ultimately, less
end-organ disease is anticipated.